Ultra-Hypofractionated RT May Offer Convenience in Elderly Breast Cancer

Commentary
Video

Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.

Ultra-hypofractionated radiotherapy (UHFRT) was well tolerated and reduced the rate of local recurrence in elderly patients with early-stage breast cancer, even among those with low endocrine therapy compliance, according to Bin Gui, MD.

CancerNetwork® spoke with Gui, a fourth-year radiation oncology resident at the Northwell Health Cancer Institute, about what he hoped colleagues would take away from results of a study assessing UHFRT among older patients with early-stage breast cancer presented at the 2024 American Society of Radiation Oncology (ASTRO) Annual Meeting.1

Gui explained that both whole breast (WBI) and accelerated partial breast irradiation (APBI) regimens were convenient and well tolerated for patients with early-stage breast cancer who were 65 years or older. He highlighted that there was 100% compliance with radiation therapy, even among those who could not comply with the addition of endocrine therapy. He concluded by stating that hypofractionated radiation may be a good option in this population, although additional prospective studies are necessary to confirm these findings.

Patients were treated using regimens employed in the phase 3 FAST-Forward trial (ISRCTN19906132) and another trial assessing APBI in breast cancer (NCT02104895).2,3

Results from the trial presented at ASTRO found that at a 10-month follow-up, no ipsilateral breast tumor recurrence (IBTR) occurred in the radiation cohort. Furthermore, there was an absence of grade 3 or 4 toxicities, and minimal low-grade (UHFRT alone, 2%; UHFRT plus ET; 0%) and late (2% vs 0%) toxicities were observed with radiation therapy.

Transcript:

In conclusion, this study demonstrates that ultra-hypofractionated radiation with either the FAST-Forward or APBI regimens offers a convenient and easily tolerated treatment approach for older [patients] who [want] to reduce the rate of their local recurrence. Furthermore, [apart from patients having] diminished compliance with endocrine therapy, their compliance with ultra-hypofractionated radiation was 100%. These regimens [may] offer patients great options to [improve] local control with low toxicity rates. Further prospective studies are necessary to confirm these initial findings.

Reference

  1. Gui B, Ojo O, Ottensoser L, et al. Ultra-Hypofractionated Radiation in Older Patients with Low Risk Early-Stage Breast Cancer. Presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting; September 29 – October 2, 2024; Washington, DC. Poster 2683
  2. Brunt AM, Haviland JS, Wheatley DA, et al. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. Health Technol Assess 2023;27(25). doi:10.3310/WWBF1044
  3. Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol. 2020;38(35):4175-4183. doi:10.1200/JCO.20.00650.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.